Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.
The main questions it aims to answer are:
* whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care)
* whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots.
Participants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication.
Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.

开始日期2024-11-12

申办/合作机构

Queen Mary University of London

ChiCTR2400082184

/ Suspended临床1期IIT

Efficacy and safety of fondaparinux in prevention of deep venous thrombosis after total knee arthroplasty study

开始日期2024-04-01

申办/合作机构-

ChiCTR2300067693

/ Suspended临床4期IIT

The efficacy and safety of fondaparinux sodium in the thromboembolic prophylaxis of patients receiving total hip and knee arthroplasty: a prospective, single arm, mono-center clinical study

开始日期2023-02-01

申办/合作机构

重庆医科大学附属第一医院

100 项与磺达肝癸钠相关的临床结果

登录后查看更多信息

100 项与磺达肝癸钠相关的转化医学

登录后查看更多信息

100 项与磺达肝癸钠相关的专利（医药）

登录后查看更多信息

2,058

项与磺达肝癸钠相关的文献（医药）

2025-10-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands

Article

作者: Nguyen, Hien M ; Philip, Livia ; Abdulsalam, Hawau ; Singh, Kartikey

Platelet factor 4 (PF4) is a natural chemokine that binds to negatively charged glycosaminoglycans (GAGs), including the anticoagulant heparin. The formation of the PF4-heparin complex elicits an immune response that results in platelet activation, leading to serious thrombotic complications. This study explores the structure-activity relationships (SAR) of sulfated pseudo-tetrasaccharide aminoglycoside ligands. The binding interactions of these synthetically designed compounds with heparanase (HPSE) and PF4 were systematically elucidated. Through computational design, a library of sulfated aminoglycoside ligands was synthesized in 10-13 steps from readily available paromomycin and neomycin. The SAR studies revealed that hydroxyl-capped ligands interacted with the fondaparinux-binding domain of PF4, while hydrophobic-capped ligands bound to the heparin-binding domain. Notably, steric hindrance imposed by hydrophobic groups impedes the binding of the ligands to PF4's shallow binding site. In contrast, these hydrophobic-capped ligands demonstrated a strong binding affinity for HPSE. The most selective ligands reduced the viability of HPSE-overexpressing cancer cells, highlighting their potential efficacy in modulating the enzymatic activity of HPSE. This SAR study provides a foundational framework for the design of sulfated aminoglycoside-based therapeutics with minimized adverse effects associated with PF4.

2025-06-30·Qatar medical journal

Cerebral venous sinus thrombosis as a complication of heparin-induced thrombocytopenia in myasthenia gravis: A rare and complex case

Article

作者: Zammar, Khaled ; Alnakhala, Sadi Y. ; Khalil, Osama M. ; AbuAlrob, Majd A. ; Gumander, Abdullah Mantawil ; Hussain, Suhail ; Qazakzeh, Abdullah I AL

Background: Cerebral venous sinus thrombosis (CVST) is an uncommon yet critical complication, especially when arising from heparin-induced thrombocytopenia (HIT). In patients with preexisting conditions such as myasthenia gravis (MG), this correlation adds further complexity to clinical management and outcomes.Case presentation: We report a unique case of CVST induced by HIT in a patient with an established diagnosis of MG. Following plasma exchange therapy, which included heparin administration, the patient developed symptoms indicative of CVST. Diagnostic imaging confirmed thrombosis in the cerebral venous sinuses. Management involved the immediate discontinuation of heparin and the initiation of fondaparinux, leading to effective anticoagulation and clinical improvement.Discussion: This case illustrates the rare intersection of CVST and HIT within the context of MG, underscoring the potential risks associated with heparin therapy in vulnerable patient populations. Early recognition of the signs is essential, as these conditions, in combination, demand prompt and specialized interventions to prevent serious complications.Conclusion: The successful management of this complex case demonstrates the importance of heightened awareness and proactive strategies in patients with MG undergoing heparin therapy. This report advocates for careful monitoring and tailored treatment to mitigate risks in similarly complex clinical scenarios.

2025-06-01·American journal of ophthalmology case reports

Maculopathy after long-term use of fondaparinux, a heparin mimetic and heparanase inhibitor

Article

作者: Davis, Janet L ; Barakat, Mark ; Rosenfeld, Philip J ; Lin, Benjamin R ; Rivera-Grana, Erick ; Zhou, Wenting

Purpose:

To report maculopathy associated with the long-term use of fondaparinux, a heparin mimetic and inhibitor of the extracellular matrix enzyme, heparanase.

Observations:

A 41-year-old woman receiving thrice weekly injections of fondaparinux as prophylaxis against deep vein thrombosis for 9 years noticed gray spots in her vision without metamorphopsias. On exam, there was bilateral altered macular pigmentation with speckled hyperpigmentation. Optical coherence tomography revealed irregular thickening of the retinal pigment epithelium. Blue autofluorescence photography demonstrated symmetric well-defined plaques of hyper-and hypoautofluorescence similar to those described in patients chronically treated with pentosan polysulfate (PPS). Review of 13 years of outside medical records confirmed no prior treatment with PPS. Two years before, optical coherence tomography (OCT) done as part of routine eye examination showed early pigmentary changes which were not felt to be clinically significant. Inherited retinal gene panel testing and mitochondrial DNA testing did not reveal pathogenic variants associated with pattern dystrophies. The maculopathy was attributed to fondaparinux due to a pharmacologic effect shared with PPS of heparanase inhibition. Thirteen months after stopping fondaparinux, there was a significant reduction in macular pigmentary changes and improvement in outer retinal abnormalities on OCT.

Conclusions and importance:

Fondaparinux is structurally and functionally related to PPS, which is also a heparin mimetic and heparanase inhibitor. Both drugs are now associated with phenotypically similar disruptions of the macular retinal pigment epitheliopathy. Although used for different clinical indications, both fondaparinux and PPS are sulfated oligosaccharides related to heparin that bind and inhibit heparanase, a critical enzyme in the extracellular matrix. This case is relevant for research into pharmacologic uses of heparanase inhibitors and monitoring for retinal disease in patients treated with them.

项与磺达肝癸钠相关的新闻（医药）

2025-06-23

·博瑞生物

博瑞医药在ADA2025发布GLP-1/GIP受体激动剂BGM0504II期积极数据及新型Amylin BGM1812临床前成果

II期数据显示，双靶点GLP-1/GIP受体激动剂BGM0504在2型糖尿病患者中，显示出在降糖和其他相关复合获益方面的综合潜质，并初步显示出优于司美格鲁肽的临床疗效；II期数据显示，双靶点GLP-1/GIP受体激动剂BGM0504在超重/肥胖非2型糖尿病成人群体中，展现出显著的体重管理潜力和代谢风险指标综合获益的潜质；胰淀素类似物BGM1812临床前数据支持其作为新一代肥胖治疗药物的开发潜力。中国苏州，2025年6月24日（北京时间）—— 创新驱动型国际化制药企业博瑞医药（BrightGene Pharmaceutical Co., Ltd.）在美国糖尿病协会（ADA）第85届科学会议上，公布了其自主研发的胰高血糖素样肽-1受体（GLP-1R）/葡萄糖依赖性促胰岛素多肽受体（GIPR）双靶点激动剂BGM0504的两项II期临床研究数据，以及新型Amylin BGM1812的临床前研究结果。两项独立的BGM0504 II期研究分别显示，该药物在2型糖尿病患者中表现出良好的降糖疗效，并初步显示出优于司美格鲁肽的临床疗效。同时在超重/肥胖非2型糖尿病成人群体中，展现出显著的体重管理潜力和代谢风险指标综合获益的潜质。BGM1812临床前数据显示，其受体激活能力显著增强，可实现强效减重，并与GLP-1/GIP双靶点激动剂产生协同作用，支持其作为新一代肥胖治疗药物开发。北京大学人民医院纪立农教授表示“BGM0504在中国成人2型糖尿病患者2期临床研究中初步显示出显著的降低患者糖化血红蛋白、空腹血糖、餐后2小时血糖、体重、收缩压/舒张压等指标；大多数不良事件严重程度为轻至中度，且无需干预即可自行缓解，未观察到低血糖或非预期的不良事件。总体风险获益评估良好。本研究结果表明BGM0504注射液不仅初步疗效显著且耐受性良好，使其有望成为2型糖尿病治疗进一步开发的强有力候选药物。在后续3期临床研究中通过优化剂量滴定周期有望进一步提升其安全性和耐受性。”博瑞医药首席执行官袁建栋博士表示“这些II期数据凸显了BGM0504作为2型糖尿病和肥胖症治疗药物的国际第一梯队潜力，包括其可能优于司美格鲁肽的疗效及良好的安全性表现。同时，BGM1812的临床前数据进一步验证了其作为新型Amylin的开发价值，彰显了我们产品管线中的更多潜力。依托我们在多肽领域的深厚积累和高效药物研发传统，博瑞医药致力于加速创新疗法开发，以满足代谢疾病等领域未被满足的临床需求。”BGM0504治疗2型糖尿病II期研究BGM0504注射液已完成的II期临床试验（CTR202232464）是一项在中国2型糖尿病患者中进行的一项多中心、随机、安慰剂双盲及阳性药开放平行对照的临床研究，阳性对照药为司美格鲁肽注射液 1.0 mg。本项研究共纳入67例，随机后实际给药64例18-65岁2型糖尿病参与者。目标剂量稳定给药12周，主要终点指标结果显示，BGM0504三个剂量组HbA1c降幅均显著优于安慰剂组，且初步优于司美格鲁肽组：5mg组-1.72%、10mg组-1.94%、15mg组-2.48%，司美格鲁肽组为-1.43%，安慰剂组为-0.28%。次要终点指标如PPG-2h、FPG、体重、HbA1c达标比例等均呈现类似趋势，HOMA2-B/IR、血脂、血压等指标亦呈现出不同改善趋势，尤其在血压改善方面表现出良好地降压效果。整体显示出，BGM0504注射液在降糖和其他相关复合获益方面的综合潜质。治疗期间不良事件多为1-2级，最常见胃肠道反应为本类产品常见的一过性腹泻、恶心和腹胀等，未发生任何低血糖或其他非预期的不良反应。BGM0504治疗肥胖症II期研究BGM0504注射液已完成的II期临床试验（CTR20233198）是一项在非2型糖尿病的超重或肥胖受试者中进行的一项多中心、随机、双盲、安慰剂平行对照的临床研究。结果显示，主要终点指标目标剂量给药24周各剂量组体重相对安慰剂组显著降低，经安慰剂调整后的LSM分别为5 mg 组: −10.77% (95% CI: −12.93 to −8.61)、−10.2 kg (−12.3 to −8.2)，10 mg 组: −16.21% (95% CI: −19.20 to −13.23)、−15.5 kg (−18.3 to −12.6)，15 mg 组: −19.78% (95% CI: −23.02 to −16.54)、−20.1 kg (−23.4 to −16.8)。并且，各剂量组患者腰围经安慰剂调整后的LSM分别减少8.0-12.98 cm（p<0.001）。此外，相关脂代谢/心血管等指标也有不同程度的综合获益，其中收缩压降低11.60-13.03 mmHg，舒张压降低5.98-7.50 mmHg（p<0.05）。次要终点进一步支持BGM0504的疗效，各剂量组整体耐受性良好，所发生的不良事件绝大多数为 1~2 级，且大多未经干预即可恢复的一过性不良事件，所发生的不良反应多见于胃肠道系统方面（GI），严重程度主要为 1 级，发生时间集中在剂量滴定阶段及目标剂量给药前4周，继续给药后可逐渐耐受。整个试验过程中未发生任何低血糖事件和其他非预期不良反应。BGM1812临床前研究临床前研究表明，BGM1812在胰淀素受体和降钙素受体上的激动剂活性（EC50）分别较petrelintide（Zealand Pharma在研药物）提高1.8倍和2.2倍。在饮食诱导的肥胖（DIO）大鼠模型中，该药物在0.012-0.12 mg/kg剂量范围内呈现剂量依赖性体重减轻效应；在0.04 mg/kg剂量下，不仅减重效果超越petrelintide，还更有利于脂肪与瘦体重比例的进一步改善。值得关注的是，在DIO模型中，BGM1812与BGM0504的联合用药方案初步展现出优于司美格鲁肽+Cagrilintide或Amycretin组合的减重持续性和疗效强度。关于BGM0504BGM0504 注射液是公司自主研发的GLP-1/GIP受体双重激动剂，可激动GIP和GLP-1下游通路，产生控制血糖、减重和治疗非酒精性脂肪性肝炎（NASH）等生物学效应，展现多种代谢疾病治疗潜力。该药物目前在中国开展针对体重管理和2型糖尿病的III期临床试验，并在美国完成US bridging 临床研究。迄今已有超1000例患者接受治疗，显示出卓越疗效和良好安全性。关于BGM1812BGM1812是一款基于AI/ML优化设计的新型Amylin，具有强效和超长效作用特点，未来有望开发为每周一次口服制剂。关于博瑞医药博瑞医药是一家参与国际竞争的创新型制药企业，是具备全产业链产品和核心药物研发技术平台的上市公司。自设立以来，博瑞医药致力于高技术壁垒的医药中间体、原料药及制剂产品的研发、生产和销售。截至目前，博瑞医药的中间体及原料药产品主要覆盖抗肿瘤、抗病毒、抗真菌、免疫抑制等治疗领域。随着公司原料药与制剂一体化战略的推进，先后已取得恩替卡韦片、注射用艾司奥美拉唑钠、注射用醋酸卡泊芬净、磺达肝癸钠注射液、奥拉西坦注射液、注射用米卡芬净钠、磷酸奥司他韦胶囊、阿加曲班注射液、磷酸奥司他韦干混悬剂、注射用伏立康唑、甲磺酸艾立布林注射液、卡前列素氨丁三醇注射液、地诺孕素片等药品批件，逐步建立起了具有全球竞争优势的产品线。前瞻性声明*本新闻稿仅为展示公司业务最新进展，不代表对于治疗方法和药品的推荐，相关药品的使用请咨询专业医师。不应赖以作为预测、研究、宣传材料或投资建议。本新闻非产品功效宣传，仅是对既定事实的陈述及科普说明。新闻信息中可能会包含某些前瞻性表述，这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务；及(b) 因任何数据、信息、资料等内容的原创性、真实性、准确性、时效性和完整性而导致的任何责任。

临床2期临床3期临床结果临床1期

2025-06-19

·李氏大药厂

兆科合肥新生产线正式启用，新质生产力助力企业续展新宏图！

6月8日，李氏大药厂控股有限公司（简称“李氏大药厂”或“集团”，股份编号：00950）全资附属公司兆科药业（合肥）有限公司（简称“兆科合肥”或“公司”）迎来又一重要里程碑——新的预灌封隔离器生产线正式投入生产运行！01打破瓶颈、产能跃升兆科合肥基地成立于1994，是集研发生产商业化为一体的综合性基地，为提升集采产品【那屈肝素钙注射液（商标名：立腾菁®）和磺达肝癸钠注射液（商标名：立畅青®）】的产能，并兼顾未来发展需要，利用四楼有限空间增加了一条高速预灌封隔离器生产线。该线灌装速度较传统设备提升约10倍，单批次15万支正常仅需6小时即可完成产品灌装，彻底化解了过往因产能不足导致的供应压力。02智能化工艺、高质量保障新的生产线采用先进的隔离器屏障技术，包材全自动消毒后自动脱包，灌装机构具备CIP/SIP功能，装量采用IPC控制，大大提高了自动化水平，并显著提升无菌保障水平；实时监控温湿度、压力等参数和自动生成电子批记录的数字化质量管理系统，符合FDA数据完整性要求；此外，该设备支持真空和机械加塞，能兼容不同规格的预充针包材和卡式瓶，柔性化的生产设计为合肥基地承接国内外CDMO业务打下基础。先进的生产工艺和严格的质控体系，将确保产品品质更加卓越、稳定，为公司高质量发展注入强劲动力。目前，新线已顺利投产运行，老线已完成使命。未来，兆科合肥继续夯实制造硬件，秉持“以人为本、尊重生命、科学创新、质量为先”的管理理念，发展新质生产力，造福患者为健康中国健康事业贡献一份力量。往期回顾◆ 中外交流越山海，学术领航促未来——2025中欧脑心联盟俱乐部：心血管病与皮肤医学专场成功举办◆ 【为爱解冻，涅槃新生】“李”我携手破冰——第25个世界渐冻人日医患交流系列活动预告◆ 中欧脑心联盟俱乐部-肺动脉高压专场◆ 精彩会议回顾|2025年ALS病例魔方第二期——基因分析与ALS诊断关于李氏大药厂- 亞太地區最具創新力的上市企業 -李氏大药厂控股有限公司（简称“李氏大药厂”或“集团”, 股份编号: 00950）成立于1994年，是一家结合了研发驱动和市场导向的生物医药集团公司，总部位于香港。李氏大药厂于2002年7月在香港联合交易所（简称：“港交所”）创业板上市，并于2010年5月成功转至港交所主板上市。李氏大药厂在中国大陆拥有两大综合性生产研发基地，即：兆科合肥基地（位于安徽省合肥市高新区）和兆科广州基地（位于广东省广州市南沙区），目前员工总数超过1100人。李氏大药厂立足中国大陆，放眼国际，通过坚实和稳固的投入建设，全面覆盖整合了药物研发、临床研究、药政注册、生产制造、销售与市场推广等各个环节。集团集中于心血管科、妇科与产科、儿科、罕见病、肿瘤科、皮肤科、精神科等多个重要疾病领域开发不同阶段的专利新药和高端仿制药。李氏大药厂与20余家国际公司建立了广泛的合作关系，目前在中国大陆、香港、澳门及台湾地区推广及销售25种包含专利新药、仿制药物及授权引进的国外已上市进口药品。李氏大药厂现有超过40个处于不同开发阶段的产品，既有自主研发产品，也有通过来自美国、欧洲及日本等公司通过授权引进进行研发、生产以及商业化的产品。李氏大药厂的使命是致力于研发新药，治疗顽疾，改善生活质量，为患者带来福音，目标成为亚洲成功的生物制药集团，提供治疗疾病和改善生活质量的创新产品。下滑查看更多免责声明：本公众号发布或转载企业宣传资讯，仅供读者参考之用，并不构成收购、购买或认购依据，并不构成任何个人化的投资劝诱或建议。因本公布全部或任何部分内容而产生或因倚赖该等内容而引致的任何损失不承担任何责任。企业文化公共关系部出品图片来源：生产现场撰稿：吴莉莉排版：樊扬波审核：杨中强、石秀年与“李”同行招商热线020-39062882

申请上市医药出海

2025-03-18

·GlobeNewswire-Health Care

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4’s multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company’s Board of Directors. “We are delighted to welcome Drs. Williams and Stewart to our Board of Directors,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “With their combined expertise spanning critical aspects of R&D and clinical development, we will benefit greatly from their strategic insights as we advance our lead clinical program for urea cycle disorders and our preclinical program for SYNGAP1-related disorders, while continuing to develop additional RNA-targeting medicines designed to upregulate gene expression and meaningfully address diseases where we believe modest increases in protein levels can have a tremendous impact on the lives of patients.” Dr. Williams commented, “CAMP4’s approach is opening exciting possibilities to upregulate gene expression, a long-sought-after and challenging feat in the field of genetic medicine. I look forward to working with the team to unlock the full potential of this approach and ultimately advance novel therapeutics to the clinic.” Dr. Stewart added, “I’m thrilled to join the CAMP4 team and support its mission of advancing programmable RNA therapeutics for genetic diseases where decreased protein expression drives disease pathophysiology. By pioneering new ways to restore gene expression, CAMP4 has the potential to bring life-changing therapies to patients who currently have limited or no disease-modifying treatment options.” With over 30 years in the biopharma industry, Dr. Williams has contributed to the development of several transformative drugs, including LEUKINE®, ENBREL®, ADCETRIS®, TECFIDERA®, APROLIX®, ELOCTATE®, and SPINRAZA®. He was previously President of R&D at Sana Biotechnology and the Founding President & CEO of Codiak BioSciences. Prior to Sana, Dr. Williams served as EVP of R&D at Biogen, and earlier in his career was CEO of ZymoGenetics (acquired by BMS), and held leadership roles at Seattle Genetics, Amgen, and Immunex. Over the course of his career, he has served on the Board of Directors and Advisory Boards of more than two dozen biotech companies. Dr. Stewart currently serves as a Senior Medical Advisor to several biopharma companies, and was most recently the Chief Medical Officer at Rhythm Pharmaceuticals. Prior to this position, he served as Head of R&D at Novelion Therapeutics. Before joining Novelion, he served as corporate Chief Medical Officer at GlaxoSmithKline. With extensive clinical development experience, he has led studies across all stages, from first-in-human trials to large Phase 4 cardiovascular outcome studies. Dr. Stewart has played a key role in the successful registration and launch of multiple therapies, including AVANDIA®, ARIXTRA®, TANZEUM®, and XOLREMDI®. Before transitioning to industry, he served as a Consultant Physician and Head of Clinical Services at the Diabetes Centre in Newcastle upon Tyne, UK, where his research was focused on lipid metabolism and type 2 diabetes. About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of rare and prevalent genetic diseases where increasing healthy protein levels may offer meaningful therapeutic benefits. Our approach allows for targeted gene upregulation by harnessing a fundamental mechanism of how genes are controlled. To increase gene expression, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans, objectives, expectations and intentions. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts Investor Relations:Sandya von der WeidLifeSci Advisorssvonderweid@lifesciadvisors.com Media:Jason Braco, Ph.D.LifeSci Communicationsjbraco@lifescicomms.com

高管变更寡核苷酸

100 项与磺达肝癸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01844	磺达肝癸钠	B01AX05	DB00569

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心绞痛	中国	Glaxo Wellcome Production SAS	2008-01-01
心肌梗塞	中国	Glaxo Wellcome Production SAS	2008-01-01
急性冠状动脉综合征	加拿大	GSK Plc	2007-03-22
血栓栓塞	澳大利亚	Aspen Pharmacare Holdings Ltd.	2002-03-25
不稳定型心绞痛	欧盟	Viatris Healthcare (Pty) Ltd.	2002-03-20
不稳定型心绞痛	冰岛	Viatris Healthcare (Pty) Ltd.	2002-03-20
不稳定型心绞痛	列支敦士登	Viatris Healthcare (Pty) Ltd.	2002-03-20
不稳定型心绞痛	挪威	Viatris Healthcare (Pty) Ltd.	2002-03-20
非ST段抬高型心肌梗死	欧盟	Viatris Healthcare (Pty) Ltd.	2002-03-20
非ST段抬高型心肌梗死	冰岛	Viatris Healthcare (Pty) Ltd.	2002-03-20
非ST段抬高型心肌梗死	列支敦士登	Viatris Healthcare (Pty) Ltd.	2002-03-20
非ST段抬高型心肌梗死	挪威	Viatris Healthcare (Pty) Ltd.	2002-03-20
肺栓塞	欧盟	Viatris Healthcare (Pty) Ltd.	2002-03-20
肺栓塞	冰岛	Viatris Healthcare (Pty) Ltd.	2002-03-20
肺栓塞	列支敦士登	Viatris Healthcare (Pty) Ltd.	2002-03-20
肺栓塞	挪威	Viatris Healthcare (Pty) Ltd.	2002-03-20
ST段抬高心肌梗死	欧盟	Viatris Healthcare (Pty) Ltd.	2002-03-20
ST段抬高心肌梗死	冰岛	Viatris Healthcare (Pty) Ltd.	2002-03-20
ST段抬高心肌梗死	列支敦士登	Viatris Healthcare (Pty) Ltd.	2002-03-20
ST段抬高心肌梗死	挪威	Viatris Healthcare (Pty) Ltd.	2002-03-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝盖受伤	临床3期	法国	GSK Plc	2008-12-01
膝盖受伤	临床3期	德国	GSK Plc	2008-12-01
膝盖受伤	临床3期	意大利	GSK Plc	2008-12-01
膝盖受伤	临床3期	荷兰	GSK Plc	2008-12-01
膝盖受伤	临床3期	俄罗斯	GSK Plc	2008-12-01
膝盖受伤	临床3期	西班牙	GSK Plc	2008-12-01
颅脑损伤	临床3期	美国	GSK Plc	2007-12-01
骨折	临床3期	美国	GSK Plc	2007-12-01
脊髓损伤	临床3期	美国	GSK Plc	2007-12-01
创伤和损伤	临床3期	美国	GSK Plc	2007-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02744092 (CANVAS, CTgov)	N/A	实体瘤 \| 晚期恶性实体瘤 \| 肺栓塞 ... 更多	811	rivaroxaban+Edoxaban+Apixaban+Dabigatran (Randomized Arm 1 (DOACs))	繭衊獵鹽簾鹽醖壓繭獵 = 鬱壓鑰築壓艱醖糧築遞願鬱積遞繭衊鏇製膚鑰 (範齋鬱齋膚膚願餘繭繭, 繭襯顧顧願蓋網構繭遞 ~ 艱築壓遞鑰餘鑰壓築壓) 更多	-	2023-10-03
				Warfarin+Fondaparinux+Enoxaparin+Dalteparin (Randomized Arm 2 (LMWH))	繭衊獵鹽簾鹽醖壓繭獵 = 願鹹鬱廠糧醖夢鏇糧醖願鬱積遞繭衊鏇製膚鑰 (範齋鬱齋膚膚願餘繭繭, 網範襯廠積艱獵鑰餘獵 ~ 膚選襯憲齋糧憲積遞簾) 更多
NCT04406389 (IMPACT, CTgov)	临床4期	新型冠状病毒感染	14	Unfractionated heparin+Fondapariniux+Enoxaparin sodium (Intermediate Dose Prophylaxis)	齋鹽鏇簾襯鬱壓鏇蓋衊 = 餘鏇繭廠淵鏇淵齋餘憲膚鏇齋築憲淵蓋製獵網 (簾遞願憲顧顧壓醖鏇繭, 網鑰製製鹽鬱廠憲積夢 ~ 簾醖鹽鏇鹹醖繭觸窪鏇) 更多	-	2023-09-21
				Unfractionated heparin+Fondapariniux+Argatroban+Enoxaparin sodium (Therapeutic Dose Anticoagulation)	齋鹽鏇簾襯鬱壓鏇蓋衊 = 淵網鹽構鏇壓築壓鬱壓膚鏇齋築憲淵蓋製獵網 (簾遞願憲顧顧壓醖鏇繭, 構糧獵鹽鬱範獵鏇選觸 ~ 鏇鏇簾艱壓艱簾鹽遞夢) 更多
ISTH2023	N/A	血栓栓塞	85	Fondaparinux	鑰廠獵艱鹽糧構繭糧襯(積構鏇築蓋繭鹹觸廠鬱) = 遞廠積範壓夢壓艱範築蓋願鹽憲憲獵齋簾鏇鏇 (繭鹹醖獵鑰積選膚鬱鬱 ) 更多	-	2023-06-24
ISTH2023	N/A	抗磷脂综合征	46	Fondaparinux	餘願艱築範願廠淵鬱鹹(顧願糧餘顧鬱獵壓築獵) = 鏇積遞襯網鏇網淵繭鏇顧鏇鏇製鑰築醖遞鹹淵 (糧糧鹽積襯網齋艱膚膚 ) 更多	-	2023-06-24
NCT00789399 (CTgov)	N/A	冠心病 \| 静脉血栓形成 \| 静脉血栓栓塞	78	Fondaparinux (Fondaparinux)	範繭窪願艱鏇鑰顧獵鬱 = 衊窪夢衊壓衊餘製夢齋憲夢顧獵觸壓構憲網網 (餘淵鹽膚觸蓋鹹顧夢願, 鏇鹹積鬱選鬱築夢廠膚 ~ 觸齋衊壓膚糧顧遞簾網) 更多	-	2022-09-08
				Placebo (Placebo)	範繭窪願艱鏇鑰顧獵鬱 = 積顧鬱網糧鑰糧憲夢鏇憲夢顧獵觸壓構憲網網 (餘淵鹽膚觸蓋鹹顧夢願, 選醖糧淵網製壓選壓選 ~ 淵鹽構廠繭選製窪鏇艱) 更多
ESC2022	N/A	新型冠状病毒感染 \| 危重病 \| 凝血障碍 D-dimer	465	D-dimer-driven fondaparinux	壓鏇膚獵糧獵鹹願鹽願(網築製築遞廠鹽鹽淵簾) = 壓顧鑰醖觸觸夢餘鬱遞膚願艱餘艱範鑰齋壓範 (淵獵窪淵壓顧積蓋衊衊 ) 更多	不佳	2022-08-27
				Standard prophylactic-dose fondaparinux	壓鏇膚獵糧獵鹹願鹽願(網築製築遞廠鹽鹽淵簾) = 鬱網顧鬱選鑰艱壓壓製膚願艱餘艱範鑰齋壓範 (淵獵窪淵壓顧積蓋衊衊 ) 更多
ONCOTEV (ISTH2020)	N/A	静脉血栓栓塞	368	Fondaparinux	網鹹膚鬱選襯鑰選鹽憲(繭繭醖壓遞範憲壓襯蓋) = 構選齋構簾廠膚壓艱夢獵顧繭簾齋醖鏇壓獵觸 (鬱積衊齋獵築構簾齋構 )	-	2020-07-12
				Enoxaparin	網鹹膚鬱選襯鑰選鹽憲(繭繭醖壓遞範憲壓襯蓋) = 窪觸衊齋鹹鑰膚繭選構獵顧繭簾齋醖鏇壓獵觸 (鬱積衊齋獵築構簾齋構 )
ISTH2020	N/A	蛋白质S缺乏	4	Fondaparinux 2.5 mg	鹹觸製願鹹範齋構艱糧(衊願醖獵積觸築衊憲構) = 壓廠鹽製齋觸鹹膚構淵艱遞餘憲淵選艱鏇繭衊 (選遞獵鑰鹹築繭獵遞醖 )	积极	2020-07-12
ISTH2019	N/A	肝素诱导血小板减少	89	Fondaparinux	簾糧簾選淵獵遞夢鏇簾(製鬱壓鹽願鹹襯願齋積) = 淵遞壓窪餘醖鑰顧齋顧願構淵選願齋鹹淵醖網 (鹽壓醖簾製鏇願淵衊膚 )	-	2019-06-10
EASL2019	N/A	门静脉血栓形成	123	Fondaparinux	願夢積觸廠膚構獵製構(壓膚遞顧窪衊鹹鬱餘積) = One patient treated with FPX and 3 patients in LMWH had a major bleeding episodes 鏇遞憲廠餘簾齋艱範選 (齋遞齋衊憲淵艱窪鹹壓 )	积极	2019-04-13
				Low Molecular Weight Heparin (LMWH)